Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Identification of novel targets to improve glioblastoma therapy

Project description

Identifying targets for glioblastoma treatment

Glioblastoma (GBM) is the most common malignant brain tumour in adults, with standard treatment involving surgery, chemotherapy, and radiation. The median survival is around 15 months, highlighting the urgent need for new therapies. A major challenge is the presence of brain tumour stem cells (BTSCs), which can evade treatment and contribute to tumour growth. Currently, there are no therapies specifically targeting BTSCs. With the support of the Marie Skłodowska-Curie Actions programme, the INTIGT project will investigate a new signalling pathway that regulates BTSCs, aiming to identify potential targets for their eradication. This research has the potential to deliver innovative insights for GBM patients, offering hope for improved treatments and future clinical trials.

Objective

Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts, GBM tumours remain incurable and the median survival rate of GBM patients remains only ~15 months. This dismal clinical outcome underscores the urgent need for novel therapeutic strategies for GBM. At the cellular level, GBM tumours contain a rare population of self-renewing, highly invasive stem cells termed brain tumour stem cells (BTSCs). BTSCs are endowed with properties to proliferate, spur the growth of new tumours, and at the same time, evade IR and chemotherapy. Thus eradicating BTSCs in tumour bulk represents a promising approach to fight brain cancer at its roots. However, there are presently no treatments targeting BTSCs in GBM. Recent preliminary data obtained by the applicant led to the hypothesis that a novel signalling pathway, controls BTSC behaviour and represents a promising target to eradicate BTSCs. Thus, the applicant will join the Bordeaux institute of oncology (BRIC) at University of Bordeaux to test this hypothesis, under the supervision of Pr. Bikfalvi. The host, the supervisor and the candidate represents the perfect match to realise this proposal. The project is designed to bring forth a two-way transfer of knowledge between the host and the candidate. The advanced techniques and transferable skills that the candidate acquires through this research will largely broaden his competencies and increase his employability as an independent researcher in the field of neuro-oncology. Results generated through this proposal will be innovative and of clinical relevance for GBM patients. This study has the potential to open new therapeutic avenues and pave the way for future clinical trials for better treatment of these deadly tumours.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 211 754,88
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)